{"id":2213,"date":"2026-06-09T18:00:00","date_gmt":"2026-06-09T21:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2213"},"modified":"2026-06-09T18:00:00","modified_gmt":"2026-06-09T21:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-esofagica-ivor-lewis-mckeown-thlt-esd-rt-cisplatina","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-esofagica-ivor-lewis-mckeown-thlt-esd-rt-cisplatina\/","title":{"rendered":"PGRSS esof\u00e1gica: Ivor-Lewis, McKeown, ESD"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica esof\u00e1gica que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica esof\u00e1gica<\/strong> + esofagectomia Ivor-Lewis 2-campos<\/strong> + McKeown 3-campos<\/strong> + transhiatal Orringer THLT<\/strong> + ESD endoscopic submucosal dissection<\/strong> + CROSS protocolo neoadjuvante carbo+paclitaxel+RT<\/strong> + brachy intersticial Iridium-192<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (carcinoma escamoso es\u00f4fago + adenoCa Barrett + GIST esof\u00e1gico raro) + Grupo A4 (linfa cervical bilateral + mediastinal alta-m\u00e9dia-baixa + abdominal cel\u00edaca) + Grupo C (Iridium-192 brachy + I-131 met\u00e1stase) + Grupo E (perfuro bi\u00f3psia + ESD + ressectosc\u00f3pio). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + linfadenectomia 3-campos<\/strong> + subdimensionam ESD endosc\u00f3pico<\/strong> + perdem rastreabilidade tumor es\u00f4fago<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS esof\u00e1gica opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (carcinoma escamoso 70-80% Brasil + adenoCa Barrett 20-30% + GIST raro), A4 (linfadenectomia 3-campos cervical + mediastinal + abdominal), C (Iridium-192 brachy intersticial + I-131 PRRT), E (ESD Olympus EndoCut + Erbe VIO 300D + IT-knife + Hook-knife + Triangle-tip-knife + Dual-knife), CROSS (carboplatina AUC2 + paclitaxel 50 mg\/m\u00b2 + RT 41,4 Gy\/23 fr Lista C5).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica esof\u00e1gica, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos esof\u00e1gicos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS esof\u00e1gica tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 carcinoma escamoso+adeno<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nEsc+Barrett<\/td>\n<\/tr>\n
A4 linfa 3-campos<\/td>\n4-11 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCervical+mediast+abd<\/td>\n<\/tr>\n
C Iridium-192+I-131<\/td>\n0,5-1,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nLDR\/HDR+CNEN<\/td>\n<\/tr>\n
E ESD endosc\u00f3pico<\/td>\n1-3 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nOlympus+Erbe+knives<\/td>\n<\/tr>\n
CROSS Lista C5<\/td>\n1,5-4 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nCarbo+pacli+RT<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 12-32,5 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica esof\u00e1gica m\u00e9dia porte.<\/p>\n

A1 carcinoma escamoso + adenoCa Barrett: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS esof\u00e1gica \u00e9 A1. Padr\u00e3o setorial inclui (a) carcinoma escamoso<\/strong> com 70-80% Brasil + \u00e1lcool+tabaco+achalasia+lichen+tilose + Plummer-Vinson + corrosivo soda + nutricional vitamina A\/B\/C\/Zn defici\u00eancia + alimento quente >65\u00b0C; (b) adenoCa Barrett<\/strong> com 20-30% Brasil + DRGE Doen\u00e7a Refluxo Gastroesof\u00e1gica cr\u00f4nica + Barrett’s esophagus IM intestinal metaplasia + dysplasia LGD\/HGD + ERC eradica\u00e7\u00e3o radiofrequ\u00eancia Barrx Medtronic + EMR endoscopic mucosal resection; (c) subs\u00edtio anat\u00f4mico<\/strong> cervical 5% + tor\u00e1cico superior 15% + m\u00e9dio 50% + inferior 30% + EGJ Jun\u00e7\u00e3o Esofagog\u00e1strica Siewert I\/II\/III; (d) estadiamento TNM 8\u00aa edi\u00e7\u00e3o<\/strong> Tis + T1a mucosa M1-M3 + T1b submucosa SM1-SM3 + T2 muscular pr\u00f3pria + T3 advent\u00edcia + T4a pleura+peric\u00e1rdio+diafragma + T4b traqueia+aorta+v\u00e9rtebra; (e) descarte sub-fluxos<\/strong> com pr\u00e9-pesagem + saco branco leitoso + identifica\u00e7\u00e3o A1+SUBS\u00cdTIO+TNM+CID C15 + lacre + rastreabilidade.<\/p>\n

Cl\u00ednica com A1 esof\u00e1gica madura garante margem R0<\/strong> + previne recidiva mediastinal<\/strong> + otimiza esofagectomia + reconstru\u00e7\u00e3o<\/strong>. Como discutimos no post sobre oncologia<\/a>, A1 \u00e9 a base.<\/p>\n

A4 esofagectomia Ivor-Lewis + McKeown + transhiatal: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica cir\u00fargica. Padr\u00e3o setorial inclui (a) Ivor-Lewis 2-campos<\/strong> com laparotomia abdominal + toracotomia direita + anastomose intrator\u00e1cica + linfadenectomia 2-campos abdominal+mediastinal; (b) McKeown 3-campos<\/strong> com laparotomia abdominal + toracotomia direita + cervicotomia esquerda + anastomose cervical + linfadenectomia 3-campos cervical+mediastinal+abdominal padr\u00e3o ouro Jap\u00e3o; (c) THLT transhiatal Orringer<\/strong> com laparotomia abdominal + cervicotomia esquerda + dissec\u00e7\u00e3o romba mediastinal + anastomose cervical + sem toracotomia + reduz complica\u00e7\u00e3o pulmonar; (d) MIE Minimally Invasive Esophagectomy<\/strong> com videolaparoscopia + videotoracoscopia + rob\u00f3tica Da Vinci Xi + RAMIE Robot-Assisted MIE; (e) reconstru\u00e7\u00e3o<\/strong> com gastric pull-up tubo g\u00e1strico isoperist\u00e1ltico + c\u00f3lon esquerdo+direito interposi\u00e7\u00e3o + jejuno Roux-en-Y interposi\u00e7\u00e3o + pyloroplasty Heineke-Mikulicz drenagem.<\/p>\n

Cl\u00ednica com Ivor-Lewis+McKeown+THLT madura escala linfadenectomia 3-campos 25-40 LN<\/strong> + previne f\u00edstula anastom\u00f3tica 5-15%<\/strong> + otimiza retorno degluti\u00e7\u00e3o<\/strong>. Conex\u00e3o com hospital especializado<\/a>.<\/p>\n

ESD endosc\u00f3pico + CROSS neoadjuvante + brachy: o est\u00e1gio minimamente invasivo+quimiorradio<\/h2>\n

A terceira camada \u00e9 ESD+CROSS+brachy. Padr\u00e3o setorial inclui (a) ESD Endoscopic Submucosal Dissection<\/strong> com Olympus EndoCut Q + Erbe VIO 300D + ICC 200 + IT-knife 1+2+nano + Hook-knife + Triangle-tip-knife + Dual-knife J + ITC EMR cap-fitted + ressec\u00e7\u00e3o en bloc T1a M1-M3 superficial; (b) CROSS protocolo neoadjuvante<\/strong> carboplatina AUC 2 mg\/mL\/min + paclitaxel 50 mg\/m\u00b2 semanal \u00d7 5 + RT concomitante 41,4 Gy\/23 fr 5 semanas + cirurgia 6-8 semanas p\u00f3s; (c) alternativa quimio<\/strong> com FLOT 5-FU+leucovorin+oxaliplatina+docetaxel preferencial adenoCa + MAGIC ECF epirrubicina+CDDP+5-FU + DCF docetaxel+CDDP+5-FU + FOLFOX + nivolumab Opdivo CheckMate-577 adjuvante; (d) brachy intersticial Iridium-192<\/strong> esof\u00e1gica + LDR low dose rate + HDR high dose rate + after-loading remote + cilindro esof\u00e1gico + dosimetria 3D ICRU-58 + CNEN-NN-3.05; (e) descarte ESD+CROSS+brachy<\/strong> com fragmento ESD ressecado + Lista C5 carbo+paclitaxel+5-FU+oxaliplatina+docetaxel+nivolumab + Ir-192 decaimento 74d + IPEN\/CNEN + saco amarelo+vermelho.<\/p>\n

Cl\u00ednica com ESD+CROSS+brachy madura escala diagn\u00f3stico precoce T1a<\/strong> + escala R0 ESD 90+%<\/strong> + escala pCR p\u00f3s-CROSS 25-40%<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade esof\u00e1gica<\/h2>\n

Cl\u00ednica esof\u00e1gica s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+C+E+CROSS.<\/p>\n

Cl\u00ednica esof\u00e1gica A1 + A4 + CROSS.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + linfa + neoadjuvante.<\/p>\n

Cl\u00ednica esof\u00e1gica 5 fluxos completos.<\/strong> A1+A4+C+E+CROSS + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa esof\u00e1gica + pCR 25-40% + R0 ESD 90+%.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica esof\u00e1gica<\/h2>\n

O primeiro \u00e9 a subdimensionamento CROSS Lista C5<\/strong>. Sem segrega\u00e7\u00e3o carbo+paclitaxel+5-FU+oxaliplatina+nivolumab + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional.<\/p>\n

O segundo \u00e9 a mistura A1 carcinoma + A4 3-campos linfa<\/strong>. Confunde rastreabilidade tumor + impossibilita 3-campos cervical+mediast+abd 25-40 LN + risco subestadiamento.<\/p>\n

O terceiro \u00e9 a falta de protocolo ESD ressec\u00e7\u00e3o en bloc<\/strong>. Sem rastreabilidade Olympus EndoCut+IT-knife+Hook-knife = perda R0 + risco recidiva + zero auditoria + risco perfura\u00e7\u00e3o.<\/p>\n

A regula\u00e7\u00e3o de PGRSS esof\u00e1gica no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer Es\u00f4fago<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS esof\u00e1gica 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 carcinoma escamoso 70-80%+adenoCa Barrett 20-30%+DRGE+IM+LGD\/HGD+ERC Barrx Medtronic+EMR+CID C15+TNM 8\u00aa, A4 Ivor-Lewis 2-campos+McKeown 3-campos cervical+mediast+abd+THLT Orringer+MIE+RAMIE+gastric pull-up+c\u00f3lon+jejuno+pyloroplasty Heineke-Mikulicz+25-40 LN, C Iridium-192 LDR\/HDR+I-131 PRRT+CNEN-NN-3.05, E ESD Olympus EndoCut Q+Erbe VIO 300D+IT-knife+Hook-knife+Triangle-tip+Dual-knife J+EMR cap-fitted, CROSS carbo AUC2+paclitaxel 50mg\/m\u00b2\u00d75+RT 41,4Gy\/23fr+FLOT+MAGIC ECF+nivolumab Opdivo CheckMate-577 Lista C5.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS oncologia esof\u00e1gica: Ivor-Lewis + McKeown + ESD + RT. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2212,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,3044,3045,2856],"class_list":["post-2213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-esofagica","tag-ivor-lewis-2","tag-mckeown"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2213"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2213\/revisions"}],"predecessor-version":[{"id":4330,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2213\/revisions\/4330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2212"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}